scispace - formally typeset
K

Kamalika Moulick

Researcher at Memorial Sloan Kettering Cancer Center

Publications -  14
Citations -  1198

Kamalika Moulick is an academic researcher from Memorial Sloan Kettering Cancer Center. The author has contributed to research in topics: Chaperone (protein) & Apoptosis. The author has an hindex of 10, co-authored 14 publications receiving 1122 citations. Previous affiliations of Kamalika Moulick include Kettering University & University of North Carolina at Greensboro.

Papers
More filters
Journal ArticleDOI

Roles of heat-shock protein 90 in maintaining and facilitating the neurodegenerative phenotype in tauopathies.

TL;DR: P35, a neuronal protein that activates cyclin-dependent protein kinase 5 through complex formation leading to aberrant Tau phosphorylation, and that of mutant but not WT Tau protein is maintained in tauopathies by Hsp90, leading to a reduction of the pathogenic activity of these proteins and results in elimination of aggregated Tau.
Journal ArticleDOI

Affinity-based proteomics reveal cancer-specific networks coordinated by Hsp90

TL;DR: This work uses PU-H71 affinity capture to design a proteomic approach that, when combined with bioinformatic pathway analysis, identifies dysregulated signaling networks and key oncoproteins in chronic myeloid leukemia and shows that this method can provide global insights into the biology of individual tumors, including primary patient specimens.
Journal ArticleDOI

Selective compounds define Hsp90 as a major inhibitor of apoptosis in small-cell lung cancer

TL;DR: It is discovered that small-cell lung carcinoma is a distinctive cellular system in which apoptosis is mainly regulated by Hsp90, and this results provide important evidence for a transformation-specific interplay between chaperones in regulating apoptosis in malignant cells.
Journal ArticleDOI

Design, synthesis, and evaluation of small molecule Hsp90 probes

TL;DR: The synthesis of chemical tools for three Hsp90 inhibitor classes will be useful for probing tumor-by-tumor the HSp90 complexes isolated by specific inhibitors, and will lead to better understanding of tumor specific molecular markers to aid in their clinical development.